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ABSTRACT
Objective: The aim of the study is to design, synthesize and identification of novel acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitors.
Methods: The AChE and BuChE inhibition activity of a library of piperidine and 4-thiazolidinone substituted arecoline derivatives are described. The chemical structures of newly synthesized compounds were confirmed by IR, 1H NMR, 13C NMR and mass spectral analysis.
Results: The cholinesterase inhibition assays indicated that few of the synthesized compounds exhibited considerable activity at micromolar range for AChE over BuChE. Compound 7c exhibited the most potent AChE inhibitory activity with an IC50 value of 6.62 µM for AChE and 13.78 µM for BuChE, which is comparable to the standard Neostigmine with an IC50 2.05 µM for AChE and 3.64 µM for BuChE respectively.
Conclusion: Our results clearly demonstrate that arecoline-4-thiazolidinone derivatives open up a new avenue in the field of Alzheimer’s disease.
Keywords: Arecoline analogs, Propylphosphonic anhydride (T3P®), Acetylcholinesterase/butyrylcholinesterase inhibitor, 4-thiazolidinones.
INTRODUCTIONAlzheimer’s disease (AD) is one of the most predominant irreversible neurodegenerative diseases associated with age advancement that is characterized by progressive memory loss due to neuronal deterioration and cognitive dysfunction [1]. AD develops gradually and may remain masked for several years without a diagnosis. Dysfunction of the cholinergic system, aggregation of amyloid beta proteins, hyperphosphorylation of tau proteins are the major causes of AD [2]. In humans, the pivotal signaling molecule of cholinergic transmission is acetylcholine (ACh), which is one of the prime neurotransmitters with the dual role of excitatory and inhibitory neurotransmission [3]. It majorly operates at neuromuscular junction, central nervous system and synapses in the ganglia [4]. Levels of ACh at the cholinergic synapse are regulated by cholinesterases that include acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) [5]. AChE rapidly degrades the ACh into acetate and choline, thus terminates the nerve impulse transmission [6].According to the cholinergic hypothesis, reduction of ACh is a responsible for the development of AD [7]. Inhibition of AChE could be a better strategy in improving the cognitive capacity of the AD patient [8]. The role of BuChE is not very clear but thought to be involved in the hydrolysis of ACh. In the normal conditions, AChE levels in the brain are higher than BuChE. On the contrary, AD Patients suffers from a substantial decline in the concentration of AChE and BuChE concentration remains same or may increase progressively. Furthermore, in the last few decades, cholinesterase inhibitors are the extensively used medications to prevent the advancement of AD [9]. Synthetic compounds like donepezil, tacrine, rivastigmine and galanthamine (Fig. 1), a natural alkaloid are the US-Food and Drug Administration approved cholinesterase inhibitors used to treat AD patients [10-12]. Therefore, targeting of cholinesterases is considered to be very effective in designing and formulating the therapeutic agent to break the progression of AD.
Arecoline is a natural alkaloid present in the arecanut, and it is known for its effective cognition skills enhancing effects in patients with AD and so arecoline derivatives have been considered as prime anti-AD compounds [13-15]. From past few years, our research group has been involved in designing and optimizing arecoline derivatives as cholinesterase inhibitors [16-17]. In continuation of our research work [18] in the field of medicinal chemistry for developing more potent and selective AChE/BuChE inhibitors, we have focused our attention to new class of arecoline analogues, by incorporating an extra carbon (-CH2-) atom between 4-thiazolidinone ring and arecoline nucleus. Synthesis of homologated 4-thiazolidinone substituted arecoline derivatives has been achieved for the first time as shown in the Scheme 1.
METHODSReactions were monitored by thin layer chromatography (TLC) using precoated sheets of silica gel G/UV-254 of 0.25 mm thickness (Merck 60F254) using UV light for visualization. 1H and13C NMR spectra were recorded on an NMR spectrometer operating at 400 and 100 MHz, respectively, using the residual solvent peak as a reference relative to SiMe4. Mass spectra were recorded using high resolution mass spectrometer (HRMS). Infrared spectra were recorded on Shimadzu FT-IR model 8300 spectrophotometer.Chemicals used: All chemicals were obtained from Sigma-Aldrich, Fluka and Merck Chemicals.
Synthesis
General procedure for the synthesis of tert-butyl 4-(3-((1-methyl-
1,2,5,6-tetrahydropyridin-3-yl)methyl)-4-oxothiazolidin-2-yl)piperidine-
1-carboxylate (5)To an equimolar 3-picolyl amine (1), N-Boc piperdine 4-carbaldehyde (2) and thioglycolic acid (3) in ethyl acetate, T3P® (1.2 equiv) was added at 0°C and stirred the reaction mixture at room temperature for 
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3 hrs [19]. The reaction was monitored by TLC. After the completion of the reaction, the mixture was diluted with water and neutralized by adding 10% NaHCO3 solution. The product was extracted with ethyl acetate (twice) and the combined organic layers were washed with water followed by brine solution. The organic phase was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford the product (4) which was pure enough to do the next step. Compound (4) on stirring for 3 hrs with methyl iodide (2 equiv) in dry acetone at 0°C followed by reduction using 
sodium borohydride (1.2 equiv) in methanol at −10°C afforded compound (5).
General procedure for the synthesis of compounds 7(a-r)The key intermediate (6) was synthesized by deprotection of compound (5) using HCl/ether in ether at 0°C. To a stirred solution of compound (6) in dichloromethane, triethyl amine (3 equiv) was added and cooled to 0-5°C, and then benzyl/benzoyl/benzene sulfonyl chloride (1.0 equiv) was added dropwise. The reaction mixture was stirred for 4-5 hrs at room temperature, the reaction was monitored by TLC. After completion of the reaction, the mixture was washed with water followed by brine solution. The organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to afford the title compounds 7(a-r) in good yields.
Fig. 1: Representational1H NMR and13C NMR
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3 - ( ( 1 - m e thyl - 1 , 2 , 5 , 6 - te t ra hyd ro py r i d i n - 3 - y l ) m e thyl ) - 2 - ( 1 -
(phenylsulfonyl)piperidin-4-yl)thiazolidin-4-one (7a)
Yellow gummy liquid Yield: 85% IR γmax (nujol) 3050, 1650, 1575, 1450, 1375, 1365, 1240, 1162/cm;1H NMR (400 MHz, CDCl3); δ 7.74‑7.71 (m, 3H, ArH), 7.33-7.28 (m, 2H, ArH), 5.73 (m, 1H, arecoline-C-4H), 4.54-4.50 (d, J = 4.2 Hz, 1H, thiazolidinone-CH), 3.85 (s, 2H, arecolinyl-CH2), 3.76-3.74 (dd, J = 2.8 Hz, 2H, thiazolidinone-CH2), 3.27-3.24 (m, 4H, piperidine-CH2), 2.89 (s, 2H, arecoline-C-2H2), 2.72-2.68 (m, 2H, arecoline-C-6H2), 2.56-2.51 (m, 1H, piperidine-C-4H), 2.41 (s, 3H, N-CH3), 2.25-2.20 (m, 2H, arecoline-C-5H2), 1.78-1.68 (m, 2H, piperidine-CH2), 1.65-1.52 (m, 2H, piperidine-CH2).13C NMR (100 MHz, CDCl3); δ 174.6, 136.2, 135.7, 129.0, 125.6, 123.5, 121.1, 64.4, 52.8, 50.5, 46.0, 43.5, 42.6, 41.9, 38.2, 26.4, 23.0. HRMS (ESI) m/z Calcd for C21H29N3O3S2Na [M+Na]+ 458.6033, found 458.6052.
2-(1-((4-methoxyphenyl)sulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7b)
Pale yellow liquid Yield: 86% IR γmax (nujol) 3045, 1651, 1582, 1448, 1382, 1369, 1320, 1245, 1163/cm;1H NMR (400 MHz, CDCl3); 
δ 7.70‑7.67 (d, J = 8.8 Hz, 2H, ArH), 7.01-6.99 (d, J = 8.0 Hz, 2H, ArH), 5.62 (m, 1H, arecoline-C-4 H), 4.48-4.47 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.87 (s, 3H, OCH3), 3.81 (s, 2H, arecolinyl-CH2), 3.519-3.512 (dd, J = 2.8 Hz, 2H, thiazolidinone-CH2), 3.24-3.18 (m, 4H, piperidine-CH2), 2.84 (s, 2H, arecoline-C-2H2), 2.62-2.58 (m, 2H, arecoline-C-6H2), 2.52-2.49 (m, 1H, piperidine-C-4H), 2.39 (s, 3H, N-CH3), 2.34-1.79 (m, 2H, arecoline-C-5H2), 1.77-1.39 (m, 4H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 171.4, 163.0, 129.7, 129.0, 127.6, 123.8, 114.1, 64.3, 55.6, 55.3, 51.2, 46.2, 45.2, 41.8, 38.3, 32.3, 25.3, 23.1. HRMS (ESI) m/z Calcd for C22H31N3O4S2Na [M+Na]+ 465.6292, found 465.6301.
2-(1-((4-fluorophenyl)sulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7c)
Pale brown liquid yield: 78% IR γmax (nujol) 3043, 1648, 1588, 1448, 1385, 1371, 1245, 1163, 1090/cm;1H NMR (400 MHz, CDCl3); δ 7.79‑7.77 (d, J = 8.0 Hz, 2H, ArH), 7.30-720 
(m, 2H, ArH), 5.62 (m, 1H, arecoline C-4H), 4.49-4.48 (d, J = 2.8 Hz, 1H, thiazolidinone-CH), 3.86 (s, 2H, arecolinyl-CH2), 3.80-3.79 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.24-3.20 (m, 2H, piperidine-CH2), 2.94-2.77 (m, 2H, piperidine-CH2), 2.57-2.45 (m, 3H, piperidine-C-4H and arecoline-C-2H2), 2.38 (s, 3H, N-CH3), 2.33-2.15 (m, 4H, arecoline-CH2), 1.81-1.66 (m, 2H,  piperidine-CH2), 1.51-1.33 (m, 2H, piperidine-CH2).13C NMR (100 MHz, CDCl3); δ 171.4, 166.4, 132.2, 130.3, 130.2, 116.4, 116.2, 64.2, 54.5, 51.2, 46.2, 45.7, 45.3, 38.1, 32.3, 25.4, 23.0. HRMS (ESI) m/z Calcd for C21H28FN3O3S2Na [M+Na]+ 476.5937, found 476.5942.
3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-((4-
nitrophenyl)sulfonyl) piperidin-4-yl)thiazolidin-4-one (7d)
Dark brown liquid yield: 76% IR γmax (nujol) 3040, 1648, 1587, 1535, 1449, 1385, 1370, 1360, 1242, 1165/cm;1H NMR (400 MHz, CDCl3); δ 8.12‑8.10 (d, J = 8.0 Hz, 2H, ArH), 7.98-7.96 (d, J = 7.8 Hz, 2H, ArH), 5.64 (m, 1H, arecoline C-4H), 4.51-4.50 (d, J = 3.4 Hz, 1H, thiazolidinone-CH), 3.95 (s, 2H, arecolinyl-CH2), 3.88-3.87 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.12-2.91 (m, 4H, piperidine-CH2), 2.82 (s, 2H, arecoline-C-2H2), 2.52-2.49 (m, 2H, arecoline-C-6H2), 2.45-2.36 (m, 1H, piperidine-C-4H), 2.31 (s, 3H, N-CH3), 2.21-2.13 (m, 2H, arecoline-C-5H2), 1.71-1.52 (m, 4H, piperidine CH2). 13C NMR (100 MHz, CDCl3); δ 172.0, 148.2, 140.1, 138.2, 129.1, 124.1, 121.2, 62.5, 58.4, 53.9, 48.2, 45.9, 45.6, 36.2, 33.2, 25.5, 22.9. HRMS (ESI) m/z Calcd for C21H28N4O5S2Na [M+Na]+ 503.6008, found 503.6016.
2-(1-(mesit ylsul fonyl)piper idin-4-yl) -3-((1-methyl -1 ,2 ,5 ,6-
tetrahydropyridin-3-yl)methyl) thiazolidin-4-one (7e)
Pale yellow gummy solid yield: 80% IR γmax (nujol) 3054, 2987, 1659, 1582, 1448, 1383, 1372, 1251, 1168/cm;1H NMR (400 MHz, CDCl3); 
δ 7.25 (s, 2H, ArH), 5.73‑5.69 (m, 1H, arecoline‑C‑4H), 4.79‑4.78 (d, J = 4.0 Hz, 1H, thiazolidinone-CH), 3.91 (s, 2H, arecolinyl-CH2), 3.95-3.85 (dd, J = 2.8 Hz, 2H, thiazolidinone-CH2), 3.12-2.82 (m, 4H, piperidine-CH2), 2.80 (s, 2H, arecoline-C-2H2), 2.68 (s, 6H, Ar-CH3), 2.59-2.56 (m, 2H, arecoline-C-6H2), 2.49-2.42 
Scheme 1: Synthesis of arecoline 4-thiazolidinone derivatives. R: 7a=C6H4SO2, 7b=4-OCH3-C6H4-SO2, 7c=4-F-C6H4-SO2, 7d=4-NO2-C6H4-SO2, 
7e=2,4,6-3CH3-C6H2-SO2, 7f=2,5-2Cl-C6H3-SO2, 7g=3,4,5-3OCH3-C6H2SO2, 7h=3-CH3-C6H4-CH2, 7i=3-CF3-C6H4-SO2, 7j=3,4-2Cl-C6H3-CH2, 
7k=3-NO2-C6H4-CH2, 7l=3-F-C6H4-CO, 7m=2,6-2Cl-C6H3-CO, 7n=3-Br-C6H4-CO, 7o=4-Cl-C6H4-CO, 7p=2-OCH3-C6H4-CO, 7q=3-NO2-C6H4-CO, 
7r=4-t-butyl-C6H4-CO
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(m, 1H, piperidine-C-4H), 2.35 (s, 3H, Ar-CH3), 2.32 (s, 3H, N-CH3), 2.12-1.96 (m, 2H, arecoline-C-5H2), 1.62-1.46 (m, 4H, piperidine CH2). 13C NMR (100 MHz, CDCl3); δ 170.8, 148.2, 145.1, 139.2, 138.4, 132.8, 121.8, 63.1, 59.6, 55.2, 48.4, 47.2, 45.6, 37.4, 35.2, 24.6, 22.7, 22.6. HRMS (ESI) m/z Calcd for C24H35N3O3S2Na [M+Na]+ 500.6830, found 500.6856.
2-(1-((2,5-dichlorophenyl)sulfonyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7f)
Pale brown gummy solid yield: 77% IR γmax (nujol) 3050, 1658, 1576, 1450, 1380, 1367, 1240, 1163, 730/cm;1H NMR (400 MHz, CDCl3); δ 8.03 (s, 1H, ArH), 7.46‑7.44 (d, J = 8.0 Hz, 2H, ArH), 5.68 (s, 1H, arecoline-C-4H), 4.49-4.48 (d, J = 4.0 Hz, 1H, thiazolidinone-CH), 3.93 (s, 2H, arecolinyl-CH2), 3.87-3.86 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH2), 2.87-2.79 (m, 4H, piperidine-CH2), 2.75 (s, 2H, arecoline-C-2H2), 2.64-2.51 (m, 3H, piperidine-C-4H and arecoline-C-6H2), 2.41 (s, 3H, N-CH3), 2.29-1.99 (m, 2H, arecoline-C-5H2), 1.72-1.64 (m, 2H, piperidine-CH2), 1.60-1.49 (m, 2H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 171.4, 144.0, 137.9, 133.4, 133.1, 130.7, 129.6, 129.3, 123.9, 65.6, 64.5, 54.5, 51.2, 46.3, 45.2, 38.7, 34.2, 25.3, 23.5. HRMS (ESI) m/z Calcd for C21H27Cl2N3O3S2Na [M+Na]+ 527.4934, found 527.4945.
3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-((3,4,5-
trimethoxyphenyl) sulfonyl)piperidin-4-yl)thiazolidin-4-one (7g)
Pale yellow liquid yield: 90% IR γmax (nujol) 3050, 1657, 1576, 1448, 1381, 1369, 1240, 1210, 1165/cm;1H NMR (400 MHz, CDCl3); 
δ 7.29 (s, 2H, ArH), 5.69‑5.68 (m, 1H, arecoline‑C‑4H), 4.72‑4.71 (d, J = 4.2 Hz, 1H, thiazolidinone-CH), 3.92 (s, 2H, arecolinyl-CH2), 3.89-3.85 (dd, J = 2.6 Hz, 2H, thiazolidinone-CH2), 3.88 (s, 9H, OCH3), 3.52-3.48 (m, 4H, piperidine-CH2), 2.95 (s, 2H, arecoline-C-2H2), 2.58-2.48 (m, 2H, arecoline-C-6H2), 2.36-2.32 (m, 1H, piperidine-C-4H), 2.29 (s, 3H, N-CH3), 2.14-2.09 (m, 2H, arecoline-C-5H2), 1.56-1.42 (m, 4H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 172.5, 171.8, 153.2, 139.8, 136.9, 130.5, 119.9, 112.5, 61.7, 60.1, 57.2, 54.0, 47.5, 45.2, 36.5, 34.9, 25.9, 23.3. HRMS (ESI) m/z Calcd for C24H35N3O6S2Na [M+Na]+ 548.6812, found 548.6819.
3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-
methylbenzyl)piperidin-4-yl)thiazolidin-4-one (7h)
Yellow liquid yield: 72% IR γmax (nujol) 3057, 1658, 1579, 1445, 1383, 1369, 1240, 1167/cm;1H NMR (400 MHz, CDCl3); δ 7.27 (s, 1H, ArH), 7.21-7.12 (m, 3H, ArH), 5.78-5.64 (m, 1H, arecoline-C-4H), 4.71-4.59 (d, J = 4.2 Hz, 1H, thiazolidinone-CH), 3.61 (s, 2H, arecolinyl-CH2), 3.49-3.41 (m, 4H, thiazolidinone-CH2 & benzyl-CH2), 2.98-2.96 (m, 4H, piperidine-CH2), 2.81 (s, 2H, arecoline-C-2H2), 2.57-2.51 (m, 3H, piperidine-CH and arecoline C-6H2), 2.38 (s, 3H, Ar-CH3), 2.34 (s, 3H, N-CH3), 1.95-1.90 (m, 2H, arecoline-C-5H2), 1.71-1.53 (m, 4H, piperidine CH2). 13C NMR (100 MHz, CDCl3); δ 171.1, 139.2, 138.4, 137.2, 130.4, 129.5, 128.3, 126.1, 121.5, 65.6, 62.2, 59.1, 54.3, 53.7, 48.1, 45.2, 38.1, 35.1, 26.2, 24.2, 21.5. HRMS (ESI) m/z Calcd for C22H31N3O3S2Na [M+Na]+ 472.6298, found 472.6308.
3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-((3-
(trifluoromethyl)phenyl) sulfonyl) piperidin-4-yl)thiazolidin-4-one (7i)
Dark brown liquid yield: 76% IR γmax (nujol) 3051, 1658, 1582, 1448, 1397, 1388, 1369, 1247, 1172/cm;1H NMR (400 MHz, CDCl3); 
δ 8.06 (s, 1H, ArH), 7.89‑7.69 (m, 3H, ArH), 5.62‑5.59 (m, 1H, arecoline C-4H), 4.64-4.63 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.81 (s, 2H, arecolinyl-CH2), 3.79-3.76 (dd, J = 2.6 Hz, 2H, thiazolidinone-CH2), 3.14-3.02 (m, 4H, piperidine-CH2), 2.86 (s, 2H, arecoline-C-2H2), 2.44-2.38 (m, 3H, arecoline-C-6H2 and piperidine-CH), 2.29 (s, 3H, N-CH3), 2.12-2.03 (m, 2H, arecoline-C-5H2), 1.65-1.58 (m, 4H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 171.4, 141.6, 138.5, 131.5, 130.9, 129.6, 128.1, 125.4, 125.2, 125.1, 125.0, 123.8, 121.5, 62.5, 59.1, 55.2, 48.2, 47.5, 45.2, 37.2, 35.2, 26.2, 23.1. HRMS (ESI) m/z Calcd for C22H28F3N3O3S2Na [M+Na]+ 526.6012, found 526.6019.
2-(1-(3,4-dichlorobenzyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7j)
Brown gummy solid yield: 71% IR γmax (nujol) 3049, 1658, 1586, 1451, 1392, 1369, 1249, 1176, 786/cm;1H NMR (400 MHz, CDCl3); 
δ 7.74‑7.72 (d, J = 8.2 Hz, 1H, ArH), 7.45 (s, 1H, ArH), 7.28-7.26 (d, J = 8.0 Hz, 1H, ArH), 5.66-5.62 (m, 1H, arecoline-C-4H), 4.68-4.67 (d, J = 3.6 Hz, 1H, thiazolidinone-CH), 3.89 (s, 2H, arecolinyl-CH2), 3.78-3.74 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.58 (s, 2H, benzyl-CH2), 3.18-3.12 (m, 4H, piperidine-CH2), 2.76 (s, 2H, arecoline-C-2H2), 2.60-2.56 (m, 2H, arecoline-C-6H2), 2.39-2.36 (m, 1H, piperidine-C-4H), 2.27 (s, 3H, N-CH3), 2.19-2.16 (m, 2H, arecoline-C-5H2), 1.61-1.49 (m, 4H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 170.8, 138.2, 134.8, 132.2, 129.9, 129.6, 129.2, 121.5, 64.9, 62.5, 59.3, 55.4, 54.2, 48.2, 44.8, 37.6, 35.2, 24.5, 23.9. HRMS (ESI) m/z Calcd for C22H29Cl2N3OSNa [M+Na]+ 477.4562, found 477.4569.
3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-
nitrobenzyl)piperidin-4-yl)thiazolidin-4-one (7k)
Pale yellow gummy solid yield: 70% IR γmax (nujol) 3037, 1652, 1593, 1541, 1452, 1389, 1378, 1363, 1245, 1165/cm;1H NMR (400 MHz, CDCl3); δ 8.12‑8.01 (m, 2H, ArH), 7.56‑7.51 (m, 2H, ArH), 5.66‑5.62 (m, 1H, arecoline-C-4H), 4.56-4.55 (d, J = 4.2 Hz, 1H, thiazolidinone-CH), 3.89 (s, 2H, arecolinyl-CH2), 3.92-3.81 (dd, J = 2.2 Hz, 2H, thiazolidinone-CH2), 3.64 (s, 2H, benzyl-CH2), 3.17-3.12 (m, 4H, piperidine-CH2), 2.85 (s, 2H, arecoline-C-2H2), 2.51-2.46 (m, 2H, arecoline-C-6H2), 2.35-2.31 (m, 1H, piperidine-C-4H), 2.27 (s, 3H, N-CH3), 2.22-2.18 (m, 2H, arecoline-C-5H2), 1.95-1.86 (m, 2H, piperidine-CH2), 1.56-1.42 (m, 2H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 171.6, 148.2, 136.9, 136.2, 135.2, 130.2, 125.6, 122.3, 121.6, 64.2, 62.5, 59.2, 55.2, 53.6, 47.8, 37.9, 35.2, 24.8, 23.2. HRMS (ESI) m/z Calcd for C22H30N4O3SNa [M+Na]+ 453.5636, found 453.5642.
2-(1-(3-f luorobenzoyl)piperidin-4-yl)-3-((1-methyl-1 ,2 ,5 ,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7l)
Brown gummy solid yield: 80% IR γmax (nujol) 3037, 1670, 1657, 1589, 1543, 1458, 1391, 1369, 1248, 1168/cm;1H NMR (400 MHz, CDCl3); δ 7.38‑7.32 (m, 1H, ArH), 7.21‑7.16 (m, 2H, ArH), 7.01‑6.96 (m, 1H, ArH), 5.64-5.61 (m, 1H, arecoline-C-4H), 4.59-4.55 (d, J = 4.4 Hz, 1H, thiazolidinone-CH), 3.87 (s, 2H, arecolinyl-CH2), 3.74-3.70 (dd, 
J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.15-3.09 (m, 4H, piperidine-CH2), 2.80 (s, 2H, arecoline-C-2CH2), 2.58-2.53 (m, 2H, arecoline-C-6H2), 2.46-2.43 (m, 1H, piperidine-C-4H), 2.27 (s, 3H, N-CH3), 2.22-2.17 (m, 2H, arecoline-C-5H2), 1.58-1.52 (m, 2H, piperidine-CH2), 1.39-1.35 (m, 2H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 171.6, 160.8, 138.3, 137.2, 125.9, 124.1, 122.8, 121.2, 65.6, 62.4, 59.3, 55.2, 53.6, 47.4, 42.9, 36.9, 33.8, 25.9, 24.1, 23.8. HRMS (ESI) m/z Calcd for C22H28FN3O2SNa [M+Na]+ 440.5400, found 440.5412.
2-(1-(2,6-dichlorobenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7m)
Dark brown gummy solid yield: 82% IR γmax (nujol) 3051, 1680, 1661, 1591, 1453, 1397, 1372, 1251, 1176, 789/cm;1H NMR (400 MHz, CDCl3); 
δ 7.37‑7.30 (m, 2H, ArH), 7.26‑7.25 (m, 1H, ArH), 5.88‑5.83 (m, 1H, arecoline-C-4H), 4.68-4.67 (d, J = 4.0 Hz, 1H, thiazolidinone-CH), 3.85 (s, 2H, arecolinyl-CH2), 3.81-3.79 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.20-3.16 (m, 4H, piperidine CH2), 2.86 (s, 2H, arecoline-C-2H2), 2.77-2.66 (m, 3H, piperidine-C-4H & arecoline-C-6H2), 2.33 (s, 3H, N-CH3), 2.25-2.05 (m, 2H, arecoline-C-5H2), 1.68-1.26 (m, 4H, piperidine-CH2); 13C NMR (100 MHz, CDCl3); δ 172.1, 167.9, 136.3, 135.0, 131.6, 131.5, 127.7, 125.8, 65.4, 52.1, 50.1, 46.1, 45.7, 45.3, 38.8, 32.1, 24.1, 23.2. HRMS (ESI) m/z Calcd for C22H27Cl2FN3O2SNa [M+Na]+ 491.4397, found 491.4405.
2-(1-(3-bromobenzoyl)piperidin-4-yl)-3-((1-methyl-1 ,2 ,5 ,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7n)
Pale yellow gummy solid yield: 84% IR γmax (nujol) 3053, 1684, 1665, 1596, 1453, 1397, 1372, 1254, 1176, 589/cm;1H NMR 
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(400 MHz, CDCl3); δ 8.01 (s, 1H, ArH), 7.89‑7.76 (m, 3H, ArH), 5.65‑5.63 (m, 1H, arecoline-C-4H), 4.59-4.58 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.96-3.91 (m, 4H, thiazolidinone-CH2 and arecolinyl-CH2), 3.36-3.21 (m, 4H, piperidine-CH2), 2.86 (s, 2H, arecoline-C-2H2), 2.46-2.41 (m, 3H, piperidine-C-4H and arecoline-C-6H2), 2.28 (s, 3H, N-CH3), 2.19-2.16 (m, 2H, arecoline-C-5H2), 1.48-1.39 (m, 4H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 172.1, 171.6, 141.2, 138.5, 132.9, 129.9, 129.4, 126.4, 123.1, 121.5, 61.8, 59.6, 55.2, 48.5, 45.2, 44.7, 37.4, 34.3, 26.2, 23.1. HRMS (ESI) m/z Calcd for C22H28BrN3O2SNa [M+Na]+ 501.4456, found 501.4462.
2-(1-(4-chlorobenzoyl)piperidin-4-yl)-3-((1-methyl-1 ,2 ,5 ,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7o)
Pale yellow gummy solid yield: 83% IR γmax (nujol) 3047, 1680, 1661, 1596, 1450, 1397, 1370, 1254, 1176, 789/cm;1H NMR (400 MHz, CDCl3); δ 7.88‑7.86 (d, J = 8.0 Hz, 2H, ArH), 7.74-7.72 (d, J = 8.2 Hz, 2H, ArH), 5.63-5.61 (m, 1H, arecoline-C-4H), 4.60-4.51 (d, J = 4.0 Hz, 1H, thiazolidinone-CH), 3.81 (s, 2H, arecolinyl-CH2), 3.79-3.76 (dd, 
J = 4.0 Hz, 2H, thiazolidinone-CH2), 3.41-3.37 (m, 4H, piperidine-CH2), 2.83 (s, 2H, arecoline-C-2H2), 2.62-2.57 (m, 2H, arecoline-C-6H2), 2.52-2.49 (m, 1H, piperidine-C-4H), 2.32 (s, 3H, N-CH3), 2.16-2.08 (m, 2H, arecoline-C-5H2), 1.47-1.41 (m, 4H, piperidine-CH2). 13C NMR 
(100 MHz, CDCl3); δ 170.8, 170.1, 141.2, 137.3, 134.1, 129.7, 128.9, 126.4, 121.2, 62.2, 59.2, 55.2, 48.2, 45.2, 37.2, 35.2, 26.2, 24.2. HRMS (ESI) m/z Calcd for C22H28ClN3O2SNa [M+Na]+ 456.9946, found 456.9952.
2-(1-(2-methoxybenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7p)
Pale brown gummy solid yield: 88% IR γmax (nujol) 3042, 1682, 1659, 1596, 1448, 1397, 1372, 1254, 1220, 1178/cm;1H NMR (400 MHz, CDCl3); δ 7.90‑7.84 (m, 2H, ArH), 7.25‑7.21 (m, 2H, ArH), 5.63‑5.60 (m, 1H, arecoline-C-4H), 4.64-4.63 (d, J = 4.2 Hz, 1H, thiazolidinone-CH), 3.96 (s, 2H, arecolinyl-CH2), 3.91 (s, 3H, OCH3), 3.52-3.51 (dd, 
J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.29-3.25 (m, 4H, piperidine-CH2), 2.95 (s, 2H, arecoline-C-2H2), 2.56-2.51(m, 2H, arecoline-C-6H2), 2.48-2.46 (m, 1H, piperidine-C-4H), 2.35 (s, 3H, N-CH3), 2.22-2.16 (m, 2H, arecoline-C-5H2), 1.62-1.59 (m, 2H, piperidine-CH2), 1.36-1.33 (m, 2H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 172.6, 171.4, 158.2, 138.2, 131.2, 128.5, 127.8, 121.2, 120.6, 112.6, 62.4, 59.2, 56.2, 55.1, 48.2, 45.2, 44.8, 37.2, 35.1, 25.3, 23.2. HRMS (ESI) m/z Calcd for C23H31N3O3SNa [M+Na]+ 452.5755, found 452.5761.
3-((1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methyl)-2-(1-(3-
nitrobenzoyl)piperidin-4-yl)thiazolidin-4-one (7q)
Pale brown liquid yield: 82% IR γmax (nujol) 3041, 1682, 1652, 1592, 1540, 1452, 1394, 1381, 1363, 1245, 1168/cm;1H NMR (400 MHz, CDCl3); δ 8.51 (s, 1H, ArH), 8.38‑8.32 (m, 2H, ArH), 7.76‑7.72 (m, 1H, ArH), 5.64-5.61 (m, 1H, arecoline-C-4H), 4.62-4.61 (d, J = 3.8 Hz, 1H, thiazolidinone-CH), 3.88 (s, 2H, arecolinyl-CH2), 3.69-3.64 (dd, J = 2.4 Hz, 2H, thiazolidinone-CH2), 3.26-3.20 (m, 4H, piperidine-CH2), 2.86 (s, 2H, arecoline-C-2H2), 2.61-2.57 (m, 2H, aarecoline-C-6H2), 2.42-2.38 (m, 1H, piperidine-C-4H), 2.32 (s, 3H, N-CH3), 2.28-2.24 (m, 2H, arecoline-C-5H2), 1.52-1.38 (m, 4H, piperidine-CH2). 13C NMR (100 MHz, CDCl3); δ 173.1, 171.6, 148.2, 138.2, 136.4, 132.9, 129.6, 125.2, 123.4, 121.5, 62.3, 59.2, 56.1, 48.1, 45.1, 44.9, 36.9, 35.2, 26.2, 23.8. HRMS (ESI) m/z Calcd for C22H28N4O4SNa [M+Na]+ 467.5471, found 467.5478.
2-(1-(4-tert-butylbenzoyl)piperidin-4-yl)-3-((1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)methyl)thiazolidin-4-one (7r)
Pale brown gummy solid yield: 86% IR γmax (nujol) 3045, 1688, 1662, 1597, 2234, 1451, 1399, 1372, 1330, 1254, 1220, 1178/ cm;1H NMR (400 MHz, CDCl3); δ 8.01‑7.99 (d, J = 8.0 Hz, 2H, ArH), 7.46-7.44 (d, J = 7.8 Hz, 2H, ArH), 5.64-5.61 (m, 1H, arecoline-C-4H), 4.63-4.62 (d, J = 3.6 Hz, 1H, thiazolidinone-CH), 3.85 (s, 2H, arecolinyl-CH2), 3.75-3.71 (dd, J = 2.6 Hz, 2H, thiazolidinone-CH2), 3.38-3.32 (m, 4H, piperidine-CH2), 2.85 (s, 2H, arecoline-C-2H2), 2.62-2.59 (m, 2H, arecoline-C-6H2), 2.49-2.45 (m, 1H, piperidine-C-4H), 
2.34 (s, 3H, N-CH3), 2.11-2.07 (m, 2H, arecoline-C-5H2), 1.61-1.41 (m, 4H, piperidine-CH2), 1.38 (s, 9H, t-butyl-CH3). 13C NMR (100 MHz, CDCl3); δ 172.9, 171.0, 148.1, 137.6, 136.1, 133.1, 129.1, 125.2, 122.9, 121.1, 62.2, 59.2, 55.1, 48.1, 44.9, 44.1, 37.2, 35.1, 26.2, 24.2. HRMS (ESI) m/z Calcd for C26H37N3O2SNa [M+Na]+ 478.6559, found 478.6565.
Pharmacology
In vitro inhibition studies on human AChEThe assay has been performed according to the guidelines provided in the AChE Assay Kit (DACE-100) purchased from Bio Assay systems #3191 Corporate Place, Hayward, CA 94545, USA. Briefly the assay medium (1 mL) consisted of phosphate buffer (pH 8.0), 50 µL of 0.01 M DTNB, 10 µL of enzyme, and 50 µL of 0.01 M substrate (ACh chloride solution). Briefly, the test compounds were added to the assay solution and pre incubated at 37°C with enzyme for 15 minutes followed by the addition of substrate. The activity was determined by measuring the increase of absorbance at 412 nm at 60 seconds intervals.
In vitro BuChE inhibition assayThe inhibitory activities of the prepared compounds against BuChE were performed by means of the method previously described by Ellman et al. [20] using neostigmine as the reference compound. This is based on the reaction of released thiocholine to give a colored product with a chromogenic reagent. The assay was performed in 0.1 M KH2PO4/ K2HPO4 buffers, pH 8.0, on a Shimadzu 2450 spectrophotometer. Enzyme solutions were prepared to give the concentration of 2.0 unit/ mL. The assay medium contained 0.01 M phosphate buffer (pH 8.0), DTNB, enzyme, and 0.01 M substrate BTC for BuChE. Test compounds were added to the assay medium and pre-incubated with the enzyme for 15 minutes at 37°C followed by the addition of substrate. The activity was determined by measuring the increase of absorbance at 412 nm with 1 minute interval at 37°C. The data was calculated according to the method of Ellman et al. [20].
RESULTS AND DISCUSSION
Chemistry
Previously we have reported √‑ferrite catalyzed synthesis of arecoline thiazolidinone derivatives [21] and the synthesized compounds were subjected to in vitro muscarinic receptor binding studies as well as 
in vivo pharmacological evaluation of memory and learning in male wistar rats, few of them displayed significant activity in in vitro and 
in vivo experiments. In continuation of our research work towards the development of the new class of heterocyclic compounds for the treatment of AD, we herein report propylphosphonic anhydride (T3P®) catalyzed synthesis of homologated arecoline thiazolidinone derivatives. Mild reaction condition, ease of workup, easy purification, and good yields are the noteworthy features of this protocol.Series of piperidine substituted arecoline 4-thiazolidinone derivatives were prepared by five synthetic steps. Cyclocondensation of 3-picolyl amine, thioglycolic acid with N-Boc piperdine 4-carbaldehyde was carried out in the presence of T3P® to afford 4-thiazolidinone at ambient temperature, then the pyridine ring of the compound 4 was reduced to an arecoline nucleus using earlier reported method [21] to get 5. The deprotection of compound 5 was achieved using HCl in ether to get 7. Finally using key intermediate 7 we have synthesized a good number of piperidine substituted arecoline 4-thiazolidinone derivatives 7(a-r) using substituted benzyl/benzoyl/benzene sulfonyl chlorides.
Pharmacology
Cholinesterase inhibitory activityResearch in the previous decades showed that cholinesterases are the leading and potential targets in treating AD. We investigated whether our newly synthesized compounds could inhibit AChE and BuChE. Effect of arecoline derivatives were evaluated against AChE using DACE-100 Quantichrom™ AChE assay kit based on an improved Ellman method, in which thiocholine produced by the action of AChE forms 
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a yellow color with 5,5’-dithiobis(2-nitrobenzoic acid). Half maximal inhibitory concentrations (IC50) of the compounds 7a-r along with the IC50 of positive control neostigmine are summarized in Table 1. We identified compound 7c to be the most potent inhibitor of AChE with the IC50 of 6.62 µM. Additionally, we also investigated the effect of new molecules against BuChE and 7c exhibited as a very good inhibitor with the IC50 of 13.78 µM. Apart from our lead compound 7c, other members of the series displayed significant inhibitory activity against both esterases with variable efficacy. The IC50 values for AChE inhibition are ranged from 26.85 to 6.62 µM and for BuChE from 45.87 to 13.78 µM respectively. Interestingly, all synthesized compounds are significantly more active towards AChE than BuChE, Some of the derivatives proved to be comparatively selective for AChE than to BuChE (7c >7r > 7q > 7m.).
Structure–activity relationship (SAR)SAR can be drawn from the in vitro assay for the synthesized derivatives 7(a-r). Among all the synthesized compounds, four derivatives 7c, 7m, 7r and 7q showed good AChE inhibition activity (Table 1), the potency of the molecules follows the order 7c > 7r > 7q > 7m. The remaining derivatives did not show noticeable AChE/BuChE inhibition. The compound 7c displayed most potent activity (IC50 6.62 µM for AChE and 13.78 µM for BuChE) which is comparable with the standard neostigmine (IC50 2.05 µM for AChE and 3.64 µM for BuChE). Compound 7c has a fluorine atom at para position of benzene sulfonyl group which is substituted to the amine group of the piperidine nucleus. Compounds with benzyl substitution (7h, 7j, 7k) had poor activity against both AChE and BuChE inhibition when compared to benzene sulfonyl and benzoyl derivatives. This suggests that, the presence of carbonyl or sulfonyl group between piperidine and aryl substitution played an important role for AChE/BuChE inhibition. Among the compounds with aryl sulfonyl/benzoyl group as substituents, different compounds exhibited different range of activity based on the atoms/groups attached to the phenyl ring.
CONCLUSIONIn the field of drug discovery, enzymes are often serves as excellent targets in designing therapeutic agents for various pathological conditions. The present report focus on the tailoring of cholinesterase inhibitors is targeting the AD. Many researchers have proved that, cognitive behavior can be improved using cholinesterase inhibitors in AD patients. In this study, a new group of arecoline analogues, modified at the junction of Arecoline and 4-thiazolidinone by incorporating an extra carbon linkage have been prepared and all the synthesized 
compounds were evaluated for their inhibitory efficacy against AChE and BuChE. We identified 7c as a lead compound with the good inhibitory efficacy against both cholinesterases. This confirms that the fluorine atom on the benzene sulfonyl moiety may have a considerable influence on the cholinesterase activity. Thus, further structural modification of compound 7c can be carried out to develop effective cholinesterase inhibitors.
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